Informação sobre produto
PKI-166 is a mitochondria-targeted prodrug that has been shown to be cytotoxic in vitro and in vivo. It binds to the mitochondrial membrane and causes depolarization, which leads to apoptosis. PKI-166 has also been shown to inhibit tumor growth in a rat model of subcutaneous tumors. The drug is cell type specific and does not affect normal cells such as fetal bovine or mouse embryonic fibroblasts. PKI-166 is activated by dna binding activity and can bind to DNA as well as proteins such as epidermal growth factor (EGF) and tetrazolium dye. PKI-166 has pharmacokinetic properties that are different from other drugs in its class, which include a long half-life and low clearance rate. The drug also inhibits the proliferation of carcinoma cell lines with high epidermal growth factor receptor expression levels, but not with low EGF receptor expression levels.
Propriedades químicas
Consulta técnica sobre: 3D-MHA72461 PKI-166
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
